We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner.
Astellas, a global pharmaceutical company headquartered in Japan, works across more than 70 countries in the US, Europe and Asia. They bring to the Consortium an increased mass of expertise in key research areas as well as extensive experience of innovative research partnerships. This announcement builds on their overall European strategy to become an integral part of the UK and European innovation ecosystems. Earlier this year Astellas opened a new office in Cambridge, UK, building a local presence that will provide great support for initiating new collaborations here.
Bradley Hardiman, Head of the UK Scouting Team at Astellas said,
‘I’m delighted that we have joined the Consortium. I know first-hand the fantastic science that takes place in Cambridge. Joining the Consortium will allow Astellas to access that science in a collaborative and constructive way. I’d like to thank the team at the MTI and my colleagues within Astellas for making this happen. I hope that this will be one of many great things that Astellas will accomplish within the UK and European innovation clusters’.
Tony Kouzarides, Director of the MTI, said, ‘It’s great to have Astellas on board as a member of the Milner Therapeutics Consortium. We look forward to working with them and to help them develop successful and productive collaborations with scientists here in Cambridge.